| abstract |
Drugs inhibiting autoimmune responses and/or potentiating normal immune responses through the augmentation of NKT cells, characterized by containing as the active ingredient compounds represented by general formula (I) or pharmaceutically acceptable salts thereof; and a novel process for synthesizing these compounds, wherein R1 represents hydrogen or halogeno; R2 represents hydroxy; R3 represents lower alkyl; R4 represents lower alkyl; R5 represents hydrogen or lower alkoxy; and Z represents O or S. |